The GO enrichment analysis suggested that IL-6 pretreatment before lobaplatin treatment significantly regulated kinase binding, Toll-like receptors, Hippo signaling, and mitogen-activated protein kinase binding (all p-values < 0.05) in osteosarcoma cells. The gene discussed is WNK2; the disease is osteosarcoma.